2024 BrainChip Discussion, page-8435

First 8435 Last

Share
Profile

Follow
Zacsydney

3,443 Posts.

722

27/08/24

14:46

Post #: 75396778
Share

Originally posted by manny100: ↑

Its maybe that you do not fully understand the journey for a new industry. Targets to date have actually been met.
The first target is building a solid base to launch.
The solid base is achieved by building a sound 'living' ecosystem which will be always improved. This is a moving target and BRN has so far built a sold ecosystem. This moving target has been largely met
The 2nd target of a solid base is the development of 1st class products. We have Gen2 and TENNs. These are 'living' targets and will be forever improved and new products developed. All reviews of our products have been good.
This target has been met.
The last target we are still in the early stages but working on.
In a fledgling industry such as AI at the Edge the problems faced are market demand for the product and the time from engagement to revenue. Their simply has to be sufficient demand building in a timely fashion. We are seeing green shoots here with Tata, Blue Ridge (Defense was mentioned in yesterday's ann) and Space via Frontgade.
The other constraint is the time from engagement to testing and agreeing to a deal.
The testing time for health, Autos or any product involving O,H & S can be years including passing Government regulatory testing.
We will be luckier with our Space connections as unmanned craft will not require the years of 'human safety' testing. We have already had our chips in space.
So our final target of achieving commercial deals is still on the journey with holders in the back seat always asking 'are we there yet' or ' how much longer till we get there'.
No we are not there yet. But heading towards it.
Yes, there will be holders who lose patience and sell.
Yes, there will be punters who buy willing to wait for deals.
Yes, we are priced like a business that is not there yet.
Yes, there will be punters buying our shares because they see the first 2 targets have been met (ecosystem and products) and understand that our patent portfolio especially Gen2 and TENNs in the AI at the Edge Industry expecting exponential growth is likely worth many times the current SP. Refer to Pitt Street.
Everyone will make their own call.

Expand

Appreciate your comments Manny but the ASX has always been behind the times regarding emerging and DISRUPTIVE technology. Had this been US, we won't be in the pennies. Sad state of affairs. We do hope that a proper update from Brainchip regarding the Airbus agreement is made as a proper market announcement. Dont understand why it was included in a report... Seriously
IR again hasn't used this opportunity.

Last edited by Zacsydney: 27/08/24

BRN Price at posting: 17.3¢ Sentiment: Hold Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CC9

Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20%

FFM

Firefly positioned for copper growth in Canada ahead of resource update

There are more pages in this discussion • 1,534 more messages in this thread...

First 8435 Last

Add BRN (ASX) to my watchlist

(20min delay)
Last 23.0¢		Change -0.025(9.80%)		Mkt cap ! $451.3M

Open	High	Low	Value	Volume
25.5¢	26.5¢	22.0¢	$3.918M	16.28M

Buyers (Bids)

No.	Vol.	Price($)
30	658476	23.0¢

Sellers (Offers)

Price($)	Vol.	No.
23.5¢	112520	8

View Market Depth

No.	Vol.	Price($)
29	655976	0.230
23	1327565	0.225
45	1635250	0.220
13	496118	0.215
22	724067	0.210

Price($)	Vol.	No.
0.235	112520	8
0.240	620597	14
0.245	537392	11
0.250	323570	10
0.255	404748	9

Last trade - 16.10pm 03/10/2024 (20 minute delay)

BRN (ASX) Chart

2024 BrainChip Discussion, page-8435

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20%

Firefly positioned for copper growth in Canada ahead of resource update

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

2024 BrainChip Discussion, page-8435

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20%

Firefly positioned for copper growth in Canada ahead of resource update

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News